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Abstract
Purpose—The demand for cancer care has increased among aging North American populations
as cancer treatment innovations have proliferated. Gaps between supply and demand may be
growing. This study examined whether socioeconomic status has a differential effect on waits for
surgical and adjuvant radiation treatment (RT) of breast cancer in Canada and the US.
Methods—Ontario and California cancer registries provided 929 and 984 breast cancer cases
diagnosed between 1998 and 2000 in diverse urban and rural places. Residence-based
socioeconomic data were taken from censuses. Cancer care variables were reliably abstracted from
health records: stage, receipt of surgery and RT, and waits from diagnosis to initial and initial to
adjuvant treatment. Median waits were compared within- and between-country with the non-
parametric Mann-Whitney U-test. Categorically long, age-adjusted wait comparisons used the
Mantel-Haenszel chi-square test.
Results—There were significant associations between lower socioeconomic status and longer
surgical waits, lower access to adjuvant RT and to longer RT waits across diverse places in
California. None were observed in Ontario. The two cohorts did not practically differ on access to
surgery or on surgical waits. Compared with their counterparts in California, low-income
Ontarians, particularly those in small urban places, gained greater access to RT, while high-
income Americans had shorter waits for RT.
Conclusions—This historical study contextualized Canada’s “waiting-list problems” with
evidence on breast cancer care, where lower income Americans seemed to have waited as long as
similar Canadians. Many more low-income Americans seemed to experience the longest wait of
all for adjuvant care. They simply did not receive it. In contrast to stark American socioeconomic
inequity, this study evidenced remarkable equity in Canadian breast cancer care.
Clinical and common wisdom converged in the 1990s to ignite scientific and political
interest in Canada’s “waiting-list problem.”1–3 Social and clinical forces also converged to
spur particular interest in increased waits for cancer care. The demand for cancer care
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increased among an aging Canadian population as cancer treatment innovations proliferated,
and it seemed that the gap between supply and demand may have been getting larger in
Canada than in America.4,5 However, the only previous study to test that hypothesis found
no significant treatment delay differences among women diagnosed with breast cancer in
1988 in Washington state and the province of British Columbia.6 No study has since
compared evidence on cancer care delays in Canada and the United States (US).
Breast cancer care has been most studied in this field. For a number of reasons it seems a
sentinel indicator of health care performance. The most common type of cancer among
Canadian and American women, its prognosis is excellent with early diagnosis and timely
access to the best treatments.7,8 Moreover, surgical innovations and new adjuvant radiation
therapies (RT) after both breast conserving surgery and mastectomy were advanced over the
past 20 years,4,9 so their timely access seems of legitimate clinical and policy concern. The
possibility of socioeconomic status (SES)-treatment delay associations has been a related
concern. Most Canadian studies have consistently found no relationship between SES and
waits for breast cancer surgery or adjuvant RT.10–12 The two Ontario-wide studies that did
observe very modest inverse income-wait associations, however, confounded place and
SES.13,14 Such provincial analyses do not enable one to tell which of the province’s diverse
places with their possibly different health care service endowments, the observed income-
wait gradients may best represent. Though less studied in the US, breast cancer care delays
seem much more strongly associated with SES (being poor) and related social circumstances
ranging from being under- or uninsured to being African American.15–17 The only previous
Canada-America comparative study of wait times for breast cancer care did not account for
either SES or place.6 This one will.
Consistent with a health insurance theory, shorter breast cancer survival has frequently been
observed among women of lower SES in the US, with its multitiered health care system in
which insurance inadequacy is prevalent. While a very modest to null association between
SES and breast cancer survival has been observed in Canada where necessary medical care
is universally covered.18–20 Critical between-country comparisons have also been consistent
with the health insurance explanation,21,22 demonstrating particular Canadian survival
advantages among residents of the lowest income areas.18,19 Consistent with this well
known international SES-breast cancer survival pattern, we hypothesized the following: (1)
Within-country: Wait times for initial surgery and adjuvant RT would be associated with
SES in the US (lower SES would wait longer), but not in Canada. (2) Between-country:
Where differences exist, relatively high-income Americans would be advantaged, whereas,
relatively low-income Canadians would be advantaged. This study also explored these
hypotheses across diverse places: large metropolitan areas, smaller cities and rural areas.
Methods
A prospective study of 10-yr breast cancer survival in Ontario and California provided
baseline data for this retrospective cohort of women ≥25 yr diagnosed between January 1,
1998 and December 31, 2000 (ICD-9 code = 174). It was originally powered to detect 15%
survival rate differences between three socioeconomic strata within three types of places (α
= .05 [2-tailed] and power (1 − β) = .80). Total samples of 990 each were originally required
for Ontario and California.23 Provincial and state over-samples (1,050 each), stratified by
place, were randomly selected from megalopolises with more than 5 million residents
(greater metropolitan Toronto [GMT] and the San Francisco bay area [SFBA]), small cities
with populations between 300,000 and 400,000 (Windsor-Essex county and Modesto-
Stanislaus county), and small rural places with populations of less than 10,000 and
population densities less than 400 people per km2.24–28 Key study variables that had been
routinely coded by the California Cancer Registry ([CCR] summary stage, receipt of
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surgery, RT and the dates required to calculate waits) were retrospectively abstracted in the
same manner from hospital and physician office-based patient charts for the Ontario Cancer
Registry (OCR) sample.29,30 Only 53 of the patient charts were lost to retrospective review
and these did not differ on key study variables (age, year of diagnosis, place and SES) from
the 997 that were. Respectively, 22 and 33 cases of disease that had already metastasized by
the time of diagnosis were excluded from the Ontario and California samples. Then, cases
with missing data on key study variables were excluded. All had < 5% missing data, and
such missing statuses were not associated with other key study variables. Chemotherapy
(CT) dates were prevalently missing in the Ontario (11%) and California (18%) samples, so
waits for adjuvant CT, probably not validly calculable, were not included in this study.
Respective samples for analysis were 929 and 984 in Ontario and California. Analyses of
300 or more per group were able to test this study’s hypotheses non-directionally (α = .05
[2-tailed] and power (1 − β) = .80), whereas, comparisons of groups of 100 or more could as
powerfully test directional or 1-tailed hypotheses.23 Smaller subsample analyses were
considered explorations.
The OCR and CCR surveille the most populace province and state, respectively,
contributing to their national cancer surveillance systems with demonstrated accuracy. They
both ascertain nearly all breast cancer cases (> 98%) with nearly perfect rates of microscopic
confirmation and nearly nil rates of autopsy or death certificate only ascertainment.31–36 The
CCR has also incorporated additional physician follow back procedures to more completely
capture stage and treatment data than is typical of most other US registries.37 The OCR
routinely receives hospital separation reports, pathology reports and reports from cancer
treatment centers across the province. As for the OCR enhancement, an inter-rater reliability
assessment of the first 150 patient health records was accomplished with three abstractors
trained by an experienced cancer registrar. Agreements were extremely high for both
discrete (κ coefficients ranged from .88 to .96) and continuous variables (agreement
percentages were all greater than 98%).
Census-based SES measures (census tract proportion meeting a “low-income” criterion in
Canada [census subdivisions in rural Canada] and “poverty” threshold in the US) of
demonstrated predictive validity defined relative income quantiles.18,19,38,39 These,
respective, Statistics Canada and US Census Bureau, indices of economic impoverishment
are conceptually similar. Both are based on annual household income from all sources and
adjusted for household size. The Canadian low-income cutoff is more liberal though,
approximately equal to 200% of the US poverty threshold.18,24,25 But they seemed to
achieve their analytic goal of similarly aggregating women with breast cancer into relative
tertiles, that is, low- to high-income areas within countries. Ontario SES tertiles were
defined as follows: high-income areas (low income prevalence 0.0% to 7.4% [median
household income $73,200 CAD]), middle-income (7.5–14.1% [$51,300], and low-income
(14.2–52.8% [$38,400]). California SES tertiles were defined as follows: high-income (0.8–
6.0% [$75,900 USD]), middle-income (6.1–11.6% [$51,500], and low-income (11.7–62.0%
[$34,000]).
Both the Ontario and California wait distributions were distinctly skewed. Many more
patients experienced relatively short waits than long ones. So median waits (days) were
compared within- and between-country with the non-parametric Mann-Whitney U-test.
Long wait rates were then compared with age-adjusted rate ratios (RR). All rates were
directly age-adjusted, using this study’s combined Ontario-California population of cases as
the standard. So, all of the rates within any table may be directly compared. Confidence
intervals (95% CI) around RRs were based on the Mantel-Haenszel chi-square test40,41 and,
as some of this study’s hypotheses were exploratory, 90% CIs were also reported in the text
for findings that “approached statistical significance.” The long wait criterion for surgery
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was two months. Long wait criteria for adjuvant RT were six (node negative disease) or
seven months (node positive disease) post-surgery if RT was preceded by CT, four months if
it was not.15,42–46 These previous studies suggested that such waits, comprised of systemic
delays and necessary waiting (investigations, preparation for treatment and post-surgical
recovery periods) may be associated with disease recurrence, metastases and shorter
survival. This study’s descriptive epidemiologic analyses will allow for the practical
empirical planning of future multivariate analyses of the relationships between breast cancer
care waits and survival in Canada and the United States.
Results
Surgery
Nearly every study participant received initial breast cancer-directed surgery (99%), and
such access did not differ by country, place, or SES. Surgical interventions were typically
lumpectomy for node negative disease and mastectomy for node positive disease on both
sides of the border (not shown in Table 1). The associations of country, place and SES with
surgical waits are displayed in Table 1. Overall, women with breast cancer in Ontario
typically waited 3 days longer for surgery than did their counterparts in California, and they
were also more likely to have experienced relatively long waits of 60 days or longer (RR =
1.39, 95% CI 1.00, 1.93). Though significantly different in a statistical sense, in a clinical-
policy sense overall surgical waits seemed quite similar between Ontario and California:
median waits of a little more than a week differed by only 3 days, long wait rates differed
only slightly (7.9% and 5.7%), and nine of every ten patients received surgery within seven
or six weeks, respectively.
Longer Canadian surgical waits seemed only applicable in large metropolitan areas, the
SFBA being slightly advantaged compared with GMT. No between-country differences on
median or long waits were observed in small cities or rural places. The residents of low-
income areas in California experienced longer surgical delays than did the residents of high-
income areas (typically 48 vs 35 days, 8.6% vs 4.2% waited 60 or more days, RR = 2.05,
95% CI 1.14, 3.69). No such income-surgical wait associations were observed in the
province of Ontario as a whole or in GMT, Windsor or in the province’s rural places. In
contrast, nearly significant trends suggested that low-income may be associated with longer
waits in diverse California places: SFBA (RR = 2.12, 90% CI 1.00, 4.49) and rural places
(RR = 2.29, 90% CI 1.01, 5.20). These data also suggested between-country advantages
among relatively high-income Americans in large metropolitan areas (RR = 2.19, 90% CI
1.06, 4.50) and among low-income Canadians in smaller cities (RR = 0.48, 90% CI 0.23,
0.99). Waiting times were similar across low- to high-income strata of rural places in
Ontario and California.
Adjuvant Radiation Therapy
RT receipt—The associations of country, place and SES with rates of adjuvant RT are
displayed in Table 2. For node negative breast cancer RT rates did not differ by place or
income within Ontario and the aggregate between-country rates did not differ for either
treatment group: surgery with adjuvant RT alone or surgery with adjuvant CT and RT. It did
seem that within California smaller cities such as Modesto were disadvantaged. Whether
(RR = 0.69, 95% CI 0.48, 0.99) or not (RR = 0.80, 95% CI 0.65, 0.98) they also received
CT, patients there were significantly less likely to have received RT. Patients who resided in
low-income areas of California seemed to experience similar risks of not receiving adjuvant
RT, respectively, RR = 0.77 (90% CI 0.59, 1.00) and RR = 0.77 (95% CI 0.63, 0.94). Rates
of adjuvant RT were greater among Ontario patients who resided in relatively low-income
areas than among their California counterparts for both treatment groups: no CT (RR = 1.23,
Gorey et al. Page 4
Clin Invest Med. Author manuscript; available in PMC 2010 July 27.
PM
C
 C
anada Author M
anuscript
PM
C
 C
anada Author M
anuscript
PM
C
 C
anada Author M
anuscript
95% CI 1.01, 1.39) and CT (RR = 1.39, 90% CI 1.03, 1.88). In fact, for both node negative
and node positive breast cancer, RT rates among low-income patients in Ontario did not
differ from those of high-income patients in California.
A similar pattern of findings was observed for node positive breast cancer, but the social
gradients in California were steeper and the consequent between-country differences in low-
income areas, indicative of Canadian advantage, were larger: no CT (RR = 3.18, 95% CI
1.41, 7.15) and CT (RR = 1.48, 95% CI 1.07, 2.04). Also, for node positive disease the
aggregate between-country RT rates were greater in Ontario for both treatment groups,
respectively, RR = 1.49 (95% CI 1.01, 2.19) and RR = 1.25 (95% CI 1.08, 1.45). Finally, the
Canadian access advantage seemed particularly pronounced in small cities. Patients in
Windsor, Ontario who did not receive CT, for example, were much more likely to receive
adjuvant RT than were otherwise similar patients in Modesto, California: node negative (RR
= 1.33, 95% CI 1.08, 1.63) and node positive (RR =2.53, 95% CI 1.16, 5.52) breast cancer.
It may be that health care endowments in each country’s, respective, large urban and small
rural places are similarly adequate and inadequate.
RT waits—The associations of country and SES with waits for adjuvant RT are displayed
in Table 3. The pattern of within- and between-country findings was similar for different
places, so they were aggregated in the interest of statistical power. Also, in the interest of
statistical power, two, rather than three, income groups are displayed. Waits for adjuvant RT
were consistently not associated with income in Ontario, but they consistently were in
California: node negative disease treated with surgery and adjuvant RT alone (RR = 2.76,
95% CI 1.08, 7.02), and node positive disease treated with surgery and adjuvant RT alone
(RR = 9.46, 90% CI 1.31, 68.34) or with surgery and adjuvant CT and RT (RR = 1.98, 95%
CI 1.09, 3.61). Finally, relatively high-income women with breast cancer in Ontario
typically waited one to two months longer for adjuvant RT than their counterparts in
California did. Between-country waits, however, did not typically differ significantly among
relatively low-income patients.
Discussion
Study hypotheses about the differential effects of SES on initial surgical and adjuvant RT of
breast cancer among adult women in diverse Ontario and California places were generally
supported. Relatively low SES was consistently associated with longer surgical waits, lower
access to adjuvant RT as well as to longer RT waits in California. No such associations were
observed for any of the Ontario samples. In the between-country analyses, we found that,
overall, the Canadian and American women with breast cancer did not differ much on their
access to surgery and, in fact, they were also remarkably similar on their surgical waits. As
compared with their international counterparts, however, relatively low-income Canadian
women with breast cancer tended to gain greater access to adjuvant RT, while relatively
high-income American women, who ultimately did gain access to such needed RT, tended to
have shorter waits for it. America it seems may have “waiting list problems” of its own.
However, because of America’s multiple payer structure these may operate much less
transparently than wait lists in single payer Canada. After all, could not non-treatment be
fairly characterized the longest possible “wait?”
This study’s findings differ substantially from those of the only other study that compared
waits for breast cancer care in Canada and America.6 Whereas, it found no significant
differences between Canada and the United States in treatment delays, we observed a pattern
of potentially important between-country differences. The earlier study tested only the main
effect of country. It did not account for SES in any of its analyses. Consistent with previous
Canada-US comparisons of breast cancer survival, we found that SES seems to act as an
Gorey et al. Page 5
Clin Invest Med. Author manuscript; available in PMC 2010 July 27.
PM
C
 C
anada Author M
anuscript
PM
C
 C
anada Author M
anuscript
PM
C
 C
anada Author M
anuscript
effect modifier in breast cancer treatment analyses. That is, notable country by SES
interactions were observed. Americans tended to be advantaged among the residents of
relatively high-income areas (12 comparisons: six American and one Canadian advantage,
five null), and Canadians tended to be advantaged among the residents of relatively low-
income areas (5 Canadian and 1 American advantage). It seems that the potentially
deleterious affects of low SES among women with breast cancer may be more effectively
buffered by the universally accessible Canadian health care system. The American system of
health care, on the other hand, may tend to compound the numerous advantages that those of
means already enjoy.
Methodological Issues
This study could conceivably be methodologically limited in a number of ways. First, some
of its findings that were based on relatively small samples were indeed exploratory.
However, such explorations tended to be systematically replicated by more powerful tests.
Approximately one-third each of this study’s findings could be characterized as powerful (α
< .05 [2-tailed] and power ≥ .80), marginally powerful (α < .05 [1-tailed] and power ≥ .80)
and exploratory (α < .10 [2-tailed] and power < .80). It is this study’s overall pattern of
findings, replicated across exploratory to more statistically powerful comparisons that seems
compelling. This study could also be limited by prevalent outpatient treatment incompletion
rates that have been identified as potentially problematic among North American cancer
registries.15,47 For a number of reasons we think that this study’s pattern of findings is
probably not potently confounded by this potential methodological problem. First, for this
study’s breast cancer care analyses, both the CCR and OCR were enhanced substantially
beyond the North American norm. Second, the hospital-based surgical analyses were
unlikely to have been affected at all. Third, missing data on RT was not prevalent and did
not differ significantly between countries. And fourth, CT wait-related variables were
identified as prevalently missing so such waits were not analyzed or reported. Again, we
think that it is the overall pattern of within- and between-country findings across hospital-
based and outpatient treatments that is compelling and robust. Finally, this retrospective
cohort’s long-term prospective survival analysis will not be completed for a few more years,
though this baseline analysis suggests their likely clinical significance. In the mean time,
Cancer Care Ontario, the agency responsible for the province’s cancer services, seems aware
of their policy significance. For example, through care planning efforts and increased
investments in cancer treatment centers, RT equipment and personnel, typical RT waits that
had been identified as too long in 1999 have already been shortened by more than 30%.48,49
Conclusions
This historical study contextualized Canada’s “waiting-list problems” with evidence on
breast cancer care, where relatively low-income Americans probably waited as long as or
may even have waited longer than low-income Canadians for initial surgical and adjuvant
RT. In stark contrast to American socioeconomic inequity across a number of diverse urban
and rural contexts, this study evidenced remarkable equity in the surgical and adjuvant
treatment of breast cancer in Canada during an era of increasing demand for such care.
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ad
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 b
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t d
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